TY - JOUR AU - de Graaf, Gimon AU - Postmus, Douwe AU - Westerink, Jan AU - Buskens, Erik PY - 2018 DA - 2018/06/18 TI - The early economic evaluation of novel biomarkers to accelerate their translation into clinical applications JO - Cost Effectiveness and Resource Allocation SP - 23 VL - 16 IS - 1 AB - Translating prognostic and diagnostic biomarker candidates into clinical applications takes time, is very costly, and many candidates fail. It is therefore crucial to be able to select those biomarker candidates that have the highest chance of successfully being adopted in the clinic. This requires an early estimate of the potential clinical impact and commercial value. In this paper, we aim to demonstratively evaluate a set of novel biomarkers in terms of clinical impact and commercial value, using occurrence of cardiovascular disease (CVD) in type-2 diabetes (DM2) patients as a case study. SN - 1478-7547 UR - https://doi.org/10.1186/s12962-018-0105-z DO - 10.1186/s12962-018-0105-z ID - de Graaf2018 ER -